Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach
Abstract NAFLD is a leading comorbidity in HIV with an exaggerated course compared to the general population. Tesamorelin has been demonstrated to reduce liver fat and prevent fibrosis progression in HIV-associated NAFLD. We further showed that tesamorelin downregulated hepatic gene sets involved in...
Guardado en:
Autores principales: | Lindsay T. Fourman, Takara L. Stanley, James M. Billingsley, Shannan J. Ho Sui, Meghan N. Feldpausch, Autumn Boutin, Isabel Zheng, Colin M. McClure, Kathleen E. Corey, Martin Torriani, David E. Kleiner, Colleen M. Hadigan, Raymond T. Chung, Steven K. Grinspoon |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/968ba8285b7d4c9dac1b0917f40794e7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
por: Bedimo R
Publicado: (2011) -
Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD
por: Lorena Pantano, et al.
Publicado: (2021) -
NAFLD in the Elderly
por: Alqahtani SA, et al.
Publicado: (2021) -
Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion
por: Chunye Zhang, et al.
Publicado: (2021) -
NAFLD in type 1 diabetes: overrated or underappreciated?
por: Jonathan Mertens, et al.
Publicado: (2021)